Gen-Probe Remains Neutral
We reiterate our Neutral rating on Gen-Probe Inc. (NASDAQ:GPRO). Its first-quarter 2012 adjusted earnings of 55 cents per share beat the Zacks Consensus Estimate of 51 cents. Revenues of $153.4 million were ahead of the Zacks Consensus Estimate of $151 million. Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises [...]
We reiterate our Neutral rating on Gen-Probe Inc. (NASDAQ:GPRO). Its first-quarter 2012 adjusted earnings of 55 cents per share beat the Zacks Consensus Estimate of 51 cents. Revenues of $153.4 million were ahead of the Zacks Consensus Estimate of $151 million.
Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises were partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses.
Revenues from … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards